Intravitreal injection has become a popular treatment for various retina disorders and dramatically increased over the past few years. In traditional preintravitreal injection, the preparation steps are time consuming for practitioners who perform a significant number of injections per day. Besides, lidocaine gel (L-Gel) shows a potential absorption barrier on the antibacterial effect of povidone iodine (PI).
Methods:
In this study, we describe a L/PI gel system as an alternative approach to address these issues for traditional preinjection drug administration. Lidocaine and PI are loaded in a thermoresponsive gel instilled as a liquid to the lower fornix that transitions to a stable, solid gel depot.
Results and Conclusion:
The gel demonstrated decrease in conjunctival touch sensitivity and sufficient bacteria killing with a single step, suggesting a significant decrease in the time required and less potential for drug inhibition due to sequential administration.
Get full access to this article
View all access options for this article.
References
1.
DiagoT., McCannelC.A., BakriS.J., et al.Infectious endophthalmitis after Intravitreal injection of antiangiogenic agents. Retina. 29:601–605, 2009.
2.
GrzybowskiA., ToldR., SacuS., et al.2018 update on intravitreal injections: euretina expert consensus recommendations. Ophthalmologica. 239:181–193, 2018.
3.
SchwartzS.G., FlynnH.W., and ScottI.U.Endophthalmitis after intravitreal injections. Exp. Opin. Pharmacother. 10:2119–2126, 2009.
4.
Samia-AlyE., Cassels-BrownA., MorrisD.S., StancliffeR., and SomnerJ.E.A.A survey of UK practice patterns in the delivery of intravitreal injections. Ophthalmic Physiol. Opt. 35:450–454, 2015.
5.
XingL., DorrepaalS.J., and GaleJ.Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada. Can. J. Ophthalmol. 49:261–266, 2014.
6.
FintakD.R., ShahG.K., BlinderK.J., et al.Incidence of endophthalmitis related to intravitreal injection of Bevacizumab and Ranibizumab. Retina. 28:1395–1399, 2008.
7.
MasonJ.O.I., WhiteM.F., FeistR.M., et al.Incidence of acute onset endophthalmitis following intravitreal Bevacizumab (Avastin) injection. Retina. 28:564–567, 2008.
8.
JonasJ.B., SpandauU.H., RenschF., Von BaltzS., and SchlichtenbredeF.Infectious and noninfectious endophthalmitis after intravitreal Bevacizumab. J. Ocul. Pharmacol. Ther. 23:240–242, 2007.
9.
PilliS., AthanasiosK., RichardF.S., et al.Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am. J. Ophthalmol. 145:879–882, 2008.
10.
HollingworthW., JonesT., ReevesB.C., and PetoT.A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015. BMJ Open. 7:e018289, 2017.
SpeakerM.G., and MenikoffJ.A.Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology. 98:1769–1775, 1991.
13.
SpeakerM.G., MilchF.A., ShahM.K., EisnerW., and KreiswirthB.N.Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology. 98:639–650, 1991.
14.
BodenJ.H., MyersM.L., LeeT., BushleyM.D., and TorresM.F.Effect of lidocaine gel on povidone–iodine antisepsis and microbial survival. J. Cataract Refract. Surg. 34:1773–1775, 2008.
15.
SchroederR.M., SilasM.R., ThomsonR.M., and MyersW.G.Danger of viscous gel anesthetic use prior to povidone–iodine antisepsis: best practice recommendation. J. Cataract Refract. Surg. 41:2333–2335, 2015.
16.
MillerJ.J., ScottI., FlynnH., et al.Acute-onset endophthalmitis after cataract surgery (2000–2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am. J. Ophthalmol. 139:983–987, 2005.
17.
LadE.M., MaltenfortM.G., and LengT.Effect of lidocaine gel anesthesia on endophthalmitis rates following intravitreal injection. Ophthalmic Surg. Lasers Imaging Off. J. Int. Soc. Imaging Eye. 43:115–120, 2012.
18.
InmanZ.D., and AndersonN.G.Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia. Retina. 31:669–672, 2011.
19.
DahlD.E., T.D. Jr., Lane, G., and Ferguson, D. Does lidocaine gel decrease the effectiveness of a povidone-iodine prep? Invest. Ophthalmol. Vis. Sci., 49:5629, 2008.
ShiromaH.F., TakaschimaA.K.K., FarahM.E, et al.Patient pain during intravitreal injections under topical anesthesia: a systematic review. Int. J. Retina Vitr. 3:23, 2017.
TailorR., BeasleyR., YangY., and NarendranN.Evaluation of patients' experiences at different stages of the intravitreal injection procedure—what can be improved?. Clin. Ophthalmol. Auckl. NZ. 5:1499–1502, 2011.
25.
LalwaniG.A., RosenfeldP.J., FungA.E., et al.A variable-dosing regimen with intravitreal Ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am. J. Ophthalmol. 148:43–58, 2009.
26.
FedorchakM.V., ConnerI.P., SchumanJ.S., CuginiA., and LittleS.R.Long term glaucoma drug delivery using a topically retained gel/microsphere eye drop. Sci. Rep. 7:8639, 2017.
27.
BellottiE., FedorchakM.V., VelankarS., and LittleS.R.Tuning of thermoresponsive pNIPAAm hydrogels for the topical retention of controlled release ocular therapeutics. J. Mater. Chem. B. 7:1276–1283, 2019.
28.
RussoE., and VillaC.Poloxamer hydrogels for biomedical applications. Pharmaceutics. 11:671, 2019.
29.
MonclinS.J., FarnirF., and GrauwelsM.Duration of corneal anaesthesia following multiple doses and two concentrations of tetracaine hydrochloride eyedrops on the normal equine cornea. Equine Vet. J. 43:69–73, 2011.
30.
RegnierA., BertonI., ConcordetD., and DouetJ.-Y.Effect of topical application of 2% lidocaine gel on corneal sensitivity of clinically normal equine eyes. Vet. Anaesth. Analg. 45:158–164, 2018.
31.
WieserB., TichyA., and NellA.Correlation between corneal sensitivity and quantity of reflex tearing in cows, horses, goats, sheep, dogs, cats, rabbits, and guinea pigs. Vet. Ophthalmol. 16:251–262, 2013.
32.
ZamoraJ.L.Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions. Am. J. Surg. 151:400–406, 1986.
33.
KoernerJ.C., GeorgeM.J., MeyerD.R., RoscoM.G., and HabibM.M.Povidone-iodine concentration and dosing in cataract surgery. Surv. Ophthalmol. 63:862–868, 2018.
34.
BerkelmanR.L., HollandB.W., and AndersonR.L.Increased bactericidal activity of dilute preparations of povidone-iodine solutions. J. Clin. Microbiol. 15:635–639, 1982.
35.
FergusonA.W., ScottJ.A., McGaviganJ., et al.Comparison of 5% povidone-iodine solution against 1% povidone-iodine solution in preoperative cataract surgery antisepsis: a prospective randomised double blind study. Br. J. Ophthalmol. 87:163–167, 2003.
36.
LiB., NentwichM.M., HoffmannL.E., et al.Comparison of the efficacy of povidone–iodine 1.0%, 5.0%, and 10.0% irrigation combined with topical levofloxacin 0.3% as preoperative prophylaxis in cataract surgery. J. Cataract Refract. Surg. 39:994–1001, 2013.
37.
CaldwellD., KastlP., CookJ., and SimonJ.Povidone-iodine: its efficacy as a preoperative conjunctival and periocular preparation. Ann. Ophthalmol. 16:577–580, 1984.
38.
DereklisD.L., BufidisT.A., TsiakiriE.P., and PalassopoulosS.I.Preoperative ocular disinfection by the use of povidone-iodine 5%. Acta Ophthalmol. (Copenh.). 72:627–630, 1994.
39.
XiaJ., LyonsR.J., LinM.Y., KhalifaY.M., and LaRockC.N.Combination of lidocaine gel and povidone-iodine to decrease acquired infections in procedures performed using topical anesthesia. J. Cataract. Refract. Surg. 46:1047–1050, 2020.
40.
PageM.A., and FraunfelderF.W.Safety, efficacy, and patient acceptability of lidocaine hydrochloride ophthalmic gel as a topical ocular anesthetic for use in ophthalmic procedures. Clin. Ophthalmol. Auckl. NZ. 3:601–609, 2009.
41.
KozakI., ChengL., and FreemanW.R.Lidocaine gel anesthesia for intravitreal drug administration. Retina. 25:994–998, 2005.
